Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07811180

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glucose Critical Illness Disease Attributes Immune System and Related Disorders Infections Inflammation Intensive Care Unit (ICU) Isotope Labeling Lung Diseases Metabolism Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

Location contact

Matthew T Stier, M.D., Ph.D.

CONTACT

[email protected]

615-875-4978

Matthew T Stier, M.D., Ph.D.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 or older
  • Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU
  • The participant or legally authorized representative must agree to the genetic analyses required as part of this study

Exclusion criteria

  • Pregnant
  • Prisoner or in police custody
  • Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures
  • Hemoglobin less than 8 g/dL
  • Uncontrolled hyperglycemia (persistent blood glucose >300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team
  • Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period
  • Unable to safely obtain vascular access required for study infusion and blood collection
  • Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team
  • Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives
  • Any reason which, in the opinion of the study investigator, adds additional risk to the patient

Treatment and study plan

13C6-Glucose

Drug

Compounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams.

Primary outcomes

  1. 13C6-Glucose Uptake and Metabolism in Immune Cells

    Time frame: Up to 4 hours

    Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites.

Study contacts

Contact information is provided by the study sponsor or research team.

Matthew T Stier, M.D., Ph.D.

CONTACT

[email protected]

615-875-4978

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Acronym: TORCH-ICU

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Sep 9, 2026
Registry last updated
Sep 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.